As scientific knowledge advances and regulatory guidelines evolve, with Karuna and Lykos Therapeutics anticipating approvals in Q3, this is the year where the mental health treatment landscape changes thanks to the innovative development of brand new, next-generation neuropsychiatric drugs.
Join the 150+ industry leaders attending the 7th Neuropsychiatric Drug Development conference this September to transform knowledge, share cutting-edge advancements and foster pre-competitive collaboration to innovate precision psychiatry, propel next-generation drug R&D and fuel more clinical approvals
Join Your Peers to:
Hear from 30+ brand-new speakers from the likes of Janssen, Biogen, Sumitomo Pharma America, AbbVie, Lykos Therapeutics, Boehringer Ingelheim and Compass Pathways
Broaden your knowledge with specialized case studies covering PTSD, Behavioural Symptoms Associated with FTD, Substance Use Disorders, Bipolar and many more
Engage in 12+ hours of interactive workshop discussions spanning translational EEGs, behavioural and circuit-based in vivo models, efficacy of hallucinogens, and placebo-mitigating trial designs with Sage Therapeutics, Otsuka, Lundbeck, Gilgamesh, Delix and more
Participate in either the ‘Discovery & Preclinical’ or ‘Translational & Clinical’ track of the main conference days to ensure your time out of the office is completely relevant
Discover new next-generation targets, modalities, and technologies from 8+ new presenting companies including Karuna, Click, MapLight and Sensorium Therapeutics
Who You Will Meet?
Access the Comprehensive Event Guide With 35+ Speakers, 2 Tracks of Content, 4 Pre-conference Workshops & More!
